Trial Profile
A Phase I/II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients With BRAF Wildtype Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Paclitaxel
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms NIPAWILMA
- 30 Jan 2020 Status changed from active, no longer recruiting to completed.
- 06 Jan 2020 This trial is completed in Germany (Global End Date: 17 Oct 2019), according to European Clinical Trials Database record.
- 04 Sep 2019 Planned End Date changed from 1 Jun 2018 to 1 Feb 2020.